DTIL vs EDIT
DTIL: Precision BioSciences is a clinical-stage biotechnology company leveraging its proprietary ARCUS gene editing platform to develop potentially curative in vivo therapies for genetic and infectious diseases. EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation.
Side-by-side fundamentals
| Metric | DTIL | EDIT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.32 | $2.78 | |
| Market cap as of 2026-07-23 | $189M | $421M | |
| PEG as of 2026-07-23 | -0.02 | n/a | |
| Net margin as of 2026-07-23 | -96.7% | -281.6% | DTIL higher |
| Operating margin as of 2026-07-23 | -86.8% | -281.3% | DTIL higher |
| ROE as of 2026-07-23 | -79.6% | -677.4% | DTIL higher |
| ROA as of 2026-07-23 | -34.8% | -58.3% | DTIL higher |
| Debt / equity as of 2026-07-23 | 0.29 | 12.40 | DTIL lower |
| Revenue growth (YoY) as of 2026-07-23 | -11.9% | +8.0% | EDIT higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +27.1% | EDIT higher |
| Beta as of 2026-07-23 | 1.27 | 2.08 | |
| 1-year return as of 2026-07-22 close | +50.6% | -8.3% | DTIL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.